PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.5400
+0.1800 (+5.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.3600
Open3.5200
Bid3.1200 x 800
Ask4.0000 x 1000
Day's Range3.2700 - 3.5700
52 Week Range2.5500 - 16.6500
Volume197,014
Avg. Volume338,900
Market Cap101.594M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3090
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • GlobeNewswire

    PhaseBio to Present at Stifel 2019 Healthcare Conference

    MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • PHASEBIO PHARMA (PHAS) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    PHASEBIO PHARMA (PHAS) Reports Q3 Loss, Misses Revenue Estimates

    PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress

    Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual.

  • GlobeNewswire

    PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

    MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • Hedge Funds Have Never Been This Bullish On PhaseBio Pharmaceuticals, Inc. (PHAS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On PhaseBio Pharmaceuticals, Inc. (PHAS)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GlobeNewswire

    PhaseBio Expands Executive Management Team

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the expansion of its executive management team with the appointment of Kristopher L. Hanson as Vice President, Head of Legal and Glen Burkhardt as Vice President of Human Resources.

  • Did You Manage To Avoid PhaseBio Pharmaceuticals's (NASDAQ:PHAS) 21% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid PhaseBio Pharmaceuticals's (NASDAQ:PHAS) 21% Share Price Drop?

    The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

  • GlobeNewswire

    PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial of PB2452, a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. The Phase 2b multi-center, randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of PB2452 in reversing the antiplatelet effects of ticagrelor as part of a dual antiplatelet regimen including low-dose aspirin. Additionally, the Phase 2b trial marks the beginning of United States Food and Drug Administration (“FDA”)-aligned registrational trials to support the submission of a Biologics License Application (“BLA”) for potential accelerated approval of PB2452.

  • 3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020
    TipRanks

    3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020

    In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to do before any kind of investment is to educate yourself before you make any hasty decisions. Being extra cautious could be an excellent idea.When it comes to the stock market though, “playing it safe” doesn’t always pay off and putting your money on a seemingly ‘sure bet’ that most big players are investing in, might not get you the results you are actually looking for.When you take a deeper look, you’ll notice that there are actually incredible opportunities in “smaller” and less heard of biotech stocks that can bring you closer to the sweet payday.Using TipRanks’ Stock Screener, we’ve highlighted 3 ultra-promising biotechs that are showing upside of nearly 300% and above.Gamida Cell (GMDA) Gamida Cell is a clinical-stage biopharmaceutical company that is creating and developing cell therapies for different types of cancers. The company has its own proprietary nicotinamide-based (or NAM based) cell expansion technology which is pretty much its “trade secret." NAM-based cell expansion takes the natural state of cancer cells and modifies them so that they are no longer harmful to the body.Gamida is hoping to bank on the success of its frontrunner drug ‘omidubicel’ which is expected to be a life-saving stem cell transplant solution for patients with high-risk blood cancers and bone marrow failure disorders. Omidubicel is currently in Phase 3 of its clinical trials.4-star JMP analyst Jason N. Bulter sees the Phase 3 results for omidubicel in 1H20 “as the primary value driver for the stock” and identifies “potential for success based on positive Phase 2 results.” And that’s good enough reason for Bulter to rate the stock an Outperform along with $16 price target. If the price target is reached within 12 months, that would provide a 12-month return of nearly 261%."Our..price target is derived through an NPV analysis of omidubicel sales, for which we project U.S. sales of ~$580MM by 2027 and assign a 75% probability of approval.” the analyst explained.Overall, we can see from TipRanks that Gamida has a “Strong Buy” consensus rating. In the last three months, the stock has received 22 buy ratings and seven hold ratings. Based on these ratings, the average $175 price target on X stock translates into upside of over 10% from the current share price.Gamida stock has a resounding “yes” on Wall Street. TipRanks analytics show that out of three analysts polled in the past 3 months, all three are bullish. The price target of $17.67 shows a potential upside of about nearly 300% from where the stock is currently trading. (See Gamida stock analysis on TipRanks)Nabriva Therapeutics (NBRV) Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70. (See Nabriva stock analysis on TipRanks)PhaseBio Pharmacuticals (PHAS)Rounding out our list is PhaseBio Pharmacuticals, a clinical-stage biopharmaceutical, developing treatments for orphan diseases with cardiopulmonary indications. PhaseBio's stake in the race is PB2452; medication that the company hopes will undo the negative effects of the antiplatelet drug ticagrelor. The company also has a really good second offering in PB1046; its treatment of PAH (pulmonary arterial hypertension), which creates high blood pressure in the arteries of the lungs.The company recently announced that it completed the Phase 2a clinical trial of PB2452 on healthy elderly patients and that the results have been consistent to its former Phase 1 study with younger, healthy patients. This is good news for PHAS and shows that the company is right on track with its clinical trial advances.William Blair analyst Matt Phipps believes “the completion of the Phase 2a study continues a pattern of excellent execution from company management, and we look forward to the full data presentation at an upcoming medical conference and initiation of pivotal trials in the coming months." The analyst added that “the base case...for PB2452, which assumes a peak penetration for ticagrelor of 40% of the addressable market, results in a risk-adjusted net present value of roughly $16 per share.”With that in mind, it's not surprising why Phipps reiterated an Outperform rating on PHAS stock, while boosting his price target to $7.00 (from $5.00).How does Phipps' bullish forecast echo against the word of the Street? Quite positively, it seems, as TipRanks analytics exhibit PHAS as a Strong Buy. Based on 5 analysts polled in the last 3 months, all 5 rate the stock a "buy." Meanwhile, the 12-month average price target stands at $18.33, marking nearly 340% upside from where the stock is currently trading. (See PhaseBio stock analysis on TipRanks)

  • A Look At Benzinga Pro's Most-Searched Tickers For September 26, 2019
    Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 26, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Beyond Meat Inc  (NASDAQ: BYND ) shares were ...

  • Benzinga

    The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene ...

  • GlobeNewswire

    PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary orphan diseases, today announced the completion of its Phase 2a clinical trial of PB2452. In the trial, PB2452 achieved immediate and sustained reversal of ticagrelor in older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.

  • GlobeNewswire

    Pharmacodynamics Evaluation of PhaseBio’s Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that data from an evaluation of the pharmacodynamics of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, were presented by Lisa K. Jennings, Ph.D., Professor of Medicine, University of Tennessee Health Science Center, at ESC Congress 2019 in Paris on September 1.

  • GlobeNewswire

    PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019

    MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire

    PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the receipt of written minutes from the End-of-Phase 1 meeting with the U.S. Food and Drug Administration (“FDA”) that was held in July 2019. The End-of-Phase 1 meeting was focused on gaining alignment with the FDA regarding the clinical and regulatory pathway for a potential U.S. approval of PB2452, a novel, recombinant, human monoclonal antibody antigen-binding fragment, or Fab, designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. Based on the written minutes from the End-of-Phase 1 meeting, PhaseBio believes that it has reached general agreement with the FDA on the overall design of a single, non-randomized, open label Phase 3 trial of major bleeding and urgent surgical populations to support the submission of a Biologics License Application (“BLA”) for potential accelerated approval of PB2452.

  • GlobeNewswire

    PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress

    Reported positive preliminary results from Phase 2a trial of PB2452 Received FDA Breakthrough Therapy designation for PB2452 Completed underwritten public offering of common.

  • GlobeNewswire

    PhaseBio To Report Second Quarter 2019 Financial Results and Recent Corporate Progress on August 13, 2019

    MALVERN, Pa. and SAN DIEGO, Aug. 06, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • Could The PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), then you'll have to look at the...

  • GlobeNewswire

    PhaseBio Added to Russell 2000® and 3000® Indexes

    MALVERN, Pa., and SAN DIEGO, Calif., July 01, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PhaseBio Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 18, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • Benzinga

    The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...

  • GlobeNewswire

    PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced preliminary data from its Phase 2a clinical trial of PB2452, which is the first trial of PB2452 to include older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin. Subjects in the trial resemble the patient population most likely to be treated with ticagrelor and potentially benefit from PB2452, if approved.

  • GlobeNewswire

    PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress

    Completed underwritten public offering of common stock that raised $46.2 million in net proceeds Received FDA Breakthrough Therapy designation for PB2452 Results from Phase 1.

  • GlobeNewswire

    PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019

    MALVERN, Pa. and SAN DIEGO, May 02, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • 2 Ultra-High Growth Stocks to Buy Now
    Motley Fool

    2 Ultra-High Growth Stocks to Buy Now

    Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.